Dr Sarah Wordsworth
BSc MSc PhD
Associate Professor and University Research Lecturer
Sarah Wordsworth joined the Health Economics Research Centre in January 2003 and has developed a research programme within HERC on the economics of genetic and genomic technologies. Of particular interest are the economics of translating genomic high-throughput technologies from research into clinical practice, in both cancer and cardiovascular disease. In October 2006, Sarah took up a post-doctoral fellowship from the National Institute for Health Research. This fellowship involved methodological and applied research on the economic evaluation of novel genomic technologies in the NHS. Sarah's other interests include costing methodology and trial based evaluations in the areas of eye disease, blood transfusion, cardiac surgery and surgery for obesity. Prior to this appointment, Sarah worked in the Health Economics Research Unit at the University of Aberdeen from 1995-2002, after completing her MSc in Health Economics in 1995 at the University of York.
Do health professionals value genomic testing? A discrete choice experiment in inherited cardiovascular disease
BUCHANAN JAMES. et al, (2019), European Journal of Human Genetics
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Study).
Pufulete M. et al, (2019), BMJ Open, 9
Risk attitudes and sun protection behaviour: Can behaviour be altered by using a melanoma genomic risk intervention?
Morton RL. et al, (2019), Cancer Epidemiol, 61, 8 - 13
The challenge of antimicrobial resistance: What economics can contribute
Roope LSJ. et al, (2019), Science, 364, eaau4679 - eaau4679
A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine
Fahr P. et al, (2019), Applied Health Economics and Health Policy